Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination With Letrozole as Therapy for the Treatment of Recurrent Metastatic Endometrial Cancer and Other Gynecologic Malignancies

NCT05705505 is registered in ClinicalTrials.gov with Traws Pharma, Inc. as lead sponsor.

NCT NCT05705505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05705505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination With Letrozole as Therapy for the Treatment of Recurrent Metastatic Endometrial Cancer and Other Gynecologic Malignancies
Lead sponsor
Traws Pharma, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 29, 2023
Completion date
February 28, 2026
Enrollment
60 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid endometrial cancer